BAS
TCRT icon

Brown Advisory Securities’s Alaunos Therapeutics TCRT Stock Holding History

Brown Advisory Securities’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-67
Closed -$32K – 427
2018
Q3 		$32K Buy
+67
New +$28.7K 0.01% 406

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Brown Advisory Securities's TCRT Position: Q4 2018 in Review

Brown Advisory Securities sold out of Alaunos Therapeutics (TCRT) in Q4 2018, closing a stake of 67 shares — an estimated $32K sold.

Brown Advisory Securities first reported a position in TCRT in Q3 2018 and held it in 1 quarter. The position peaked at $32K in Q3 2018. 137 funds tracked by Wall St. Rank hold TCRT as of Q4 2018.

  • Brown Advisory Securities reported no remaining Alaunos Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Brown Advisory Securities sold 67 Alaunos Therapeutics shares in Q4 2018, an estimated $32K.
  • Brown Advisory Securities first reported a position in Alaunos Therapeutics in Q3 2018 and held it in 1 quarter.
  • Brown Advisory Securities's Alaunos Therapeutics position peaked at $32K in Q3 2018.
  • 137 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2018.

Based on Brown Advisory Securities's 13F filing for Q4 2018, filed 13 Feb 2019.